Celex Oncology’s first attendance at Bio-Europe Spring 2025 follows their recent win at the 2024 EIT Health Catapult ...

The CTA approval is the first regulatory authorisation in Europe to study a non-viral gene-edited TCR-T therapy in clinical practice, paving the way for the execution of Anocca’s scalable clinical ...

In November 2024, Zealand Pharma presented detailed results from the Phase 1b 16-week multiple ascending dose (MAD) trial at the Obesity Society Annual Meeting (ObesityWeek) 2024. For the presentation ...

Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech ...

L'exercice physique est confirmé comme l’une des clés permettant de restaurer la fonction sexuelle chez les patients atteints d'un cancer de la prostate, conclut, dans le JAMA, cette équipe d’urologue ...

Idorsia Ltd (SIX: IDIA) today announced that – effective immediately – the US FDA has fully released TRYVIO™ (aprocitentan) from its REMS (Risk Evaluation and Mitigation Strategy) requirement. TRYVIO ...

EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today announced it has entered into a definitive agreement to be ...

Muscle pathology as measured by MRI continued to generally favour Elevidys across muscle groups in boys with Duchenne up to two years ...

Avance Clinical CEO Yvonne Lungershausen emphasized the importance of these new partnerships and highlighted the value of ...

The anti-inflammatory properties of probiotics found in DentPure are vital for promoting gum strength. By reducing ...

Les épidémiologistes du Barcelona Institute for Global Health (ISGlobal) nous livrent ici, dans la reue BMC Medicine, les dernières grandes données sur le COVID : près d'1 personne sur 4 infectée par ...

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced expanded data in a ...